<SEC-DOCUMENT>0001213900-25-011925.txt : 20250211
<SEC-HEADER>0001213900-25-011925.hdr.sgml : 20250211
<ACCEPTANCE-DATETIME>20250211071512
ACCESSION NUMBER:		0001213900-25-011925
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250211
FILED AS OF DATE:		20250211
DATE AS OF CHANGE:		20250211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		25607671

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0230643-6k_inspira.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the Month of February 2025 (Report No. 3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number: 001-40303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Translation of registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2 Ha-Tidhar St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ra&rsquo;anana 4366504, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9746; Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;Form
40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 11, 2025, Inspira
Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled &ldquo;Inspira Achieves Positive Results of Above 95% For
Preventing Bloodstream Infections,&rdquo; a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form
6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first, second, fourth
and fifth paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo; in the&nbsp;press release are incorporated&nbsp;by
reference into the Registrant&rsquo;s Registration Statements on Form F-3 (Registration Nos.&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390022046430/ea164081-f3_inspiratech.htm">333-266748</A>&nbsp;and&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025004023/ea0227763-f3_inspira.htm">333-284308</A>)
and Form&nbsp;S-8 (Registration Nos.&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390021044780/ea146415-s8_inspiratech.htm">333-259057</A>&nbsp;and&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024023044/ea0201791-s8_inspira.htm">333-277980</A>),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on
Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea023064301ex99-1_inspira.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on February 11, 2025, titled &ldquo;Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections.&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February 11, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea023064301ex99-1_inspira.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ON FEBRUARY 11, 2025, TITLED "INSPIRA ACHIEVES POSITIVE RESULTS OF ABOVE 95% FOR PREVENTING BLOODSTREAM INFECTIONS."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Inspira Achieves
Positive Results of Above 95% For Preventing Bloodstream Infections</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The ex-vivo testing demonstrated significant bacterial
reduction for the innovative IV dressing technology aimed at preventing bloodstream infections in critical patients</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ra&rsquo;anana, Israel - February 11, 2025</B> &ndash; Inspira&trade;
Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (&ldquo;Inspira&rdquo; or the &ldquo;Company&rdquo;), a pioneer in breakthrough life-support
technology, today announced positive initial results from its previously reported collaboration with Ennocure MedTech Ltd. to develop
a novel bio-electronic treatment for preventing bloodstream infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated
a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over a 24-hour period. The technology, which
uses physical electric stimulation rather than chemical agents, showed promising results in preventing pathogen growth on treated surfaces.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We believe that these initial results represent an important
milestone in our development of next-generation infection prevention technology,&rdquo; said Dagi Ben-Noon, CEO of Inspira. &ldquo;With
an estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide each year, we believe this novel approach
could potentially offer significant advantages in critical care settings.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The bio-electronic technology is being designed to address several
key challenges associated with traditional IV dressings, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prevention of bacterial growth through physical rather than chemical means</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Potential for extended wear time, reducing frequency of dressing changes</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Applicability to both skin surface and cannula areas</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Real-time monitoring capabilities</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Testing was conducted following adjusted standardized protocols, including
the AATCC TM100 standard for antimicrobial performance, with results showing consistent bacterial reduction under active patches compared
to controls.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Ennocure MedTech Ltd.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ennocure, is a pioneer in the development of bio-electronic wound dressing.
At the core of the technology is a proprietary bio-electronic wound dressing designed to prevent bacterial infections, while providing
remote wound monitoring &amp; infection alerts based on AI-driven personalized therapy.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Inspira</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inspira is an innovative medical technology company in the life support
and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA&trade; ART), a groundbreaking
device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute
respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA&trade; ART system aims to revolutionize critical
care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared
INSPIRA&trade; ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in both the U.S. and for Cardiopulmonary
Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company&rsquo;s HYLA&trade; blood sensor technology is designed
to provide continuous, real-time blood monitoring without the need for blood draws, targeting the $2.5 billion blood gas analyzer market.
The Company&rsquo;s pipeline products, including the INSPIRA&trade; ART (Gen 2), INSPIRA&trade; Cardi-ART, and HYLA&trade; blood sensor,
are currently in development and have not yet received regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information, please visit&nbsp;our corporate website at https://inspira-technologies.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains express or implied
forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it
discusses the potential benefits of its bio-electronic patch, that the initial results represent an important milestone in its development
of next-generation infection prevention technology and the intended design of the bio-electronic patch. These forward-looking statements
and their implications are based solely on the current expectations of the Company&rsquo;s management and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except
as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is contained under the heading &ldquo;Risk Factors&rdquo; in the Company&rsquo;s
annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;),
which is available on the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inspira Technologies &ndash; Media Relations<BR>
Email: info@inspirao2.com<BR>
Phone: +972-9-9664485</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Capital Markets &amp; Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Arx | Capital Markets Advisors<BR>
North American Equities Desk<BR>
inspira@arxadvisory.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ] -0# 2(  A$! Q$!_\0
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M )53+?\ [1S?'7_TV_$>O5O^#6KPW9Z#_P $=/@A?6T*12^+?B+\<?$U^ZJ
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MUQ>^)9=,L9]9O;LW%W?7%NMQ-,TSR2. >IT444 %%%% !1110 4444 %%%%
M'R%^S5^PC^RY^R)XY^/7Q(^ 'PW_ .$&\8_M->-7^(7QIU;_ (2;Q5KW_"7>
M+9-6\1ZVVJ?9/$.M:I9:,#J?BS7KC[)HEOI]F/MOEB 100)']>T45I5K5:\W
M4K5*E6HU&+G4G*<W&$(TX)RDV[0A",(K:,8QBM$B*=.G2CR4X1IP3DU&$5&-
MY2<I.RTO*3<F^K;84445F6%%%% !1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
